Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Eli Lilly (LLY) reduced its fourth-quarter sales guidance by 5%, lowering expectations to $13.5 billion. This figure is $400 ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...